• Exozymes priced a public offering of units at USD 18 each, with each unit comprising two common shares and one common stock purchase warrant.
• Deal includes 592,270 common shares, 296,135 warrants; gross proceeds expected at about USD 5.33 million; closing set for June 9, 2026.
• Warrants become exercisable one year from the offering, carry an exercise price of USD 11.24 per share, expire five years from issuance.
• Warrants can be redeemed at USD 0.01 per underlying share if the stock trades at USD 17.98 or higher on 20 of 30 trading days.
• Net proceeds earmarked for N-trans-caffeoyltyramine programs, R&D, working capital, corporate purposes, capital expenditures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606080900ACCESSWRNAPR_____1173868) on June 08, 2026, and is solely responsible for the information contained therein.